Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).

Baldwin DS, Loft H, Dragheim M.

Eur Neuropsychopharmacol. 2012 Jul;22(7):482-91. doi: 10.1016/j.euroneuro.2011.11.008. Epub 2011 Dec 30.

PMID:
22209361
2.
4.

A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.

Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME.

J Clin Psychiatry. 2012 Jul;73(7):953-9. doi: 10.4088/JCP.11m07470.

PMID:
22901346
5.

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.

Alvarez E, Perez V, Dragheim M, Loft H, Artigas F.

Int J Neuropsychopharmacol. 2012 Jun;15(5):589-600. doi: 10.1017/S1461145711001027. Epub 2011 Jul 18.

6.

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.

Boulenger JP, Loft H, Florea I.

J Psychopharmacol. 2012 Nov;26(11):1408-16. doi: 10.1177/0269881112441866. Epub 2012 Apr 9.

PMID:
22495621
7.

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.

Mahableshwarkar AR, Jacobsen PL, Chen Y.

Curr Med Res Opin. 2013 Mar;29(3):217-26. doi: 10.1185/03007995.2012.761600. Epub 2013 Jan 17.

PMID:
23252878
8.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
9.
10.

Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.

Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah D, Raskin J, Petit C, Demyttenaere K.

J Clin Psychiatry. 2007 Nov;68(11):1707-16.

PMID:
18052564
11.

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.

Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.

Curr Med Res Opin. 2007 Jun;23(6):1303-18. Epub 2007 Apr 27.

PMID:
17559729
12.

A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.

Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB.

Curr Med Res Opin. 2011 Oct;27(10):1849-58. doi: 10.1185/03007995.2011.609539. Epub 2011 Aug 12.

PMID:
21838411
13.

Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.

Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Hann D, Marangell LB.

Curr Med Res Opin. 2011 Oct;27(10):1859-67. doi: 10.1185/03007995.2011.609540. Epub 2011 Aug 12.

PMID:
21838410
14.

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.

Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH.

Psychopharmacology (Berl). 2015 Jun;232(12):2061-70. doi: 10.1007/s00213-014-3839-0. Epub 2015 Jan 11.

15.

The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials.

Mallinckrodt CH, Raskin J, Wohlreich MM, Watkin JG, Detke MJ.

BMC Psychiatry. 2004 Sep 8;4:26.

16.

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA.

J Clin Psychiatry. 2002 Mar;63(3):225-31.

PMID:
11926722
17.

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM.

J Psychiatr Res. 2006 Jun;40(4):337-48. Epub 2005 Nov 4.

PMID:
16271726
18.
19.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.

PMID:
16845641
20.

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.

Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA.

J Clin Psychiatry. 2002 Apr;63(4):308-15.

PMID:
12000204

Supplemental Content

Support Center